论文部分内容阅读
据2002年7月19～25日在斯德哥尔摩召开的“早老性痴呆及其相关疾病”的会议报道,TakingJanssen-Cilag-Shire 公司用加兰他敏(Reminyl)进行的3年临床研究显示,该药使早老性痴呆者认知功能的衰退进程至少延缓12个月。共有300名病人完成了为期3年的2次双盲试验。给药组与安慰剂组在试验的第12、24和36个月时用 ADAS 认知量表评分。结果表明,所有患者认知功能均呈进行性下降,不同的是给药组在各时间点的下降均比安慰剂
According to a conference on “Alzheimer’s disease and related diseases” held in Stockholm from July 19 to July 25, 2002, takingJanssen-Cilag-Shire’s 3-year clinical study with Reminyl showed that the drug Alzheimer’s cognitive function in patients with delayed decline of at least 12 months. A total of 300 patients completed two double-blind trials over a three-year period. The dosing group and the placebo group were scored on the ADAS Cognitive Scale at 12, 24 and 36 months of the trial. The results showed that all patients showed a progressive decline in cognitive function, the difference is that the administration group decreased at each time point than placebo